Health Care Innovation
Commentary
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Commentary
Banning mRNA vaccines would stop emerging cancer treatments
Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Commentary
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Commentary
The Private Sector Is Setting The PACE For Managed Care
Rising demand for long-term care is inevitable as more and more baby boomers retire. Meeting this demand will be a challenge. Recent evidence from the PACE program demonstrates that for-profit care providers can help meet this growing demand, but only if the regulatory environment allows it. Read the op-ed here.
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary
Republicans’ Free Chance To Save Sick Kids
Right now, Congress has a chance to save the lives of countless sick children—without spending a dime of taxpayer money. It could seize that opportunity by reauthorizing the Pediatric Priority Review Voucher (PPRV) program—which incentivizes companies to invest in lifesaving but financially risky treatments for rare pediatric diseases. Read the ...
Commentary
In defense of Medicaid work requirements
Republicans are considering cuts to Medicaid, the joint federal-state health plan that provides taxpayer-funded health coverage to 80 million adults and children. Many in the GOP would like to require able-bodied Medicaid beneficiaries to work in exchange for coverage. That’s a good idea. Read the entire op-ed here.
Commentary
Make Telehealth Coverage a Permanent Medicare Feature
When the Trump administration loosened telemedicine restrictions for Medicare patients in March 2020, the move was seen as temporary. The COVID-19 pandemic was in its early days. Read the op-ed here:
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Banning mRNA vaccines would stop emerging cancer treatments
Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
The Private Sector Is Setting The PACE For Managed Care
Rising demand for long-term care is inevitable as more and more baby boomers retire. Meeting this demand will be a challenge. Recent evidence from the PACE program demonstrates that for-profit care providers can help meet this growing demand, but only if the regulatory environment allows it. Read the op-ed here.
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Republicans’ Free Chance To Save Sick Kids
Right now, Congress has a chance to save the lives of countless sick children—without spending a dime of taxpayer money. It could seize that opportunity by reauthorizing the Pediatric Priority Review Voucher (PPRV) program—which incentivizes companies to invest in lifesaving but financially risky treatments for rare pediatric diseases. Read the ...
In defense of Medicaid work requirements
Republicans are considering cuts to Medicaid, the joint federal-state health plan that provides taxpayer-funded health coverage to 80 million adults and children. Many in the GOP would like to require able-bodied Medicaid beneficiaries to work in exchange for coverage. That’s a good idea. Read the entire op-ed here.
Make Telehealth Coverage a Permanent Medicare Feature
When the Trump administration loosened telemedicine restrictions for Medicare patients in March 2020, the move was seen as temporary. The COVID-19 pandemic was in its early days. Read the op-ed here:
